{"nctId":"NCT02421588","briefTitle":"Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients","startDateStruct":{"date":"2015-05"},"conditions":["Ovarian Cancer"],"count":442,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Lurbinectedin (PM01183)"]},{"label":"Arm B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pegylated liposomal doxorubicin (PLD)","Drug: Topotecan"]}],"interventions":[{"name":"Lurbinectedin (PM01183)","otherNames":[]},{"name":"Pegylated liposomal doxorubicin (PLD)","otherNames":[]},{"name":"Topotecan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\>/= 18 years\n* Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer.\n* Platinum-resistant disease (PFI: 1-6 months after last platinum-containing chemotherapy).\n* Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria\n* No more than three prior systemic chemotherapy regimens\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS) â‰¤ 2\n* Adequate hematological, renal, metabolic and hepatic function\n\nExclusion Criteria:\n\n* Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major illness\n* Prior treatment with PM01183, trabectedin, or with both PLD and topotecan.\n* Requirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival by Independent Review Committee","description":"The primary endpoint was PFS by IRC assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival by Investigator's Assessment","description":"The primary endpoint was PFS by Investigator's Assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Calculated from the date of randomization to the date of death (death event) or last contact (in this case, survival was censored on that date).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"10.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) by Independent Review Committee","description":"Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments.\n\nAntitumor activity was assessed using the RECIST v.1.1 by the appropriate method \\[computed tomography scan or magnetic resonance imaging\\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"97","spread":null}]},{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"72","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate by Investigator's Assessment","description":"Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments.\n\nAntitumor activity was assessed using the RECIST v.1.1 by the appropriate method \\[computed tomography scan or magnetic resonance imaging\\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"94","spread":null}]},{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"68","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response by Independent Review Committee","description":"Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response.\n\nBest antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments.\n\nAntitumor activity was assessed using the RECIST v.1.1 by the appropriate method \\[computed tomography scan or magnetic resonance imaging\\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response by Investigator's Assessment","description":"Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response.\n\nBest antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments.\n\nAntitumor activity was assessed using the RECIST v.1.1 by the appropriate method \\[computed tomography scan or magnetic resonance imaging\\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Response According to Tumor Marker Evaluation (CA-125)","description":"Best response according to tumor marker evaluation (CA-125): defined as the best response obtained according to GCIG criteria. Tumor marker assessments were performed at baseline and every eight weeks from randomization until evidence of PD. Progression based on serum CA-125 levels was defined on the basis of a progressive serial elevation of serum CA-125 according to:\n\nA. Patients with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart or B. Patients with elevated CA-125 before treatment, which never normalizes, must show evidence of CA-125 greater than, or equal to, 2 times the nadir value on 2 occasions at least 1 week apart or C. Patients with CA-125 in the reference range before treatment must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"94","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":92,"n":219},"commonTop":["Nausea","Fatigue","Neutropenia","Vomiting","Anaemia"]}}}